Danaher reported FY 2025 sales from continuing operations of USD 24.6 billion, up 3.0% year over year, with core sales up 2.0%. Net earnings from continuing operations were USD 3.6 billion, or USD 5.03 per diluted share, while operating profit margin was 19.1% (down 130 basis points). FY 2025 operating cash flow from continuing operations was USD 6.4 billion, and cash and cash equivalents were USD 4.6 billion as of December 31, 2025; total debt was USD 18.4 billion. By segment in FY 2025, Diagnostics sales were USD 9.9 billion (+1.5%); Biotechnology sales were USD 7.3 billion (+8.0%); and Life Sciences sales were USD 7.3 billion (flat). Danaher said it incurred incremental tariff costs in FY 2025 of less than USD 300 million and largely offset the operating profit impact through manufacturing footprint changes, supply chain adjustments, surcharges, and productivity and cost savings actions. The company also highlighted a July 2025 enactment of the OBBBA, noting no material impact on FY 2025 financial statements, and said it expects a 2026 effective tax rate of approximately 17.0% (FY 2025: 15.0%). In October 2025, a wholly owned finance subsidiary issued Swiss franc-denominated bonds with net proceeds of approximately CHF 1.2 billion (about USD 1.6 billion at pricing).
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Danaher Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000313616-26-000062), on February 24, 2026, and is solely responsible for the information contained therein.
Comments